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Abstract 
Analysis of our microRNA (miRNA) expression signature in human cancers has shown 
that guide and passenger strands of pre-miR-150, i.e., miR-150-5p and miR-150-3p, are 
significantly downregulated in cancer tissues. In miRNA biogenesis, the passenger strand of 
miRNA is degraded and is thought to have no functions. Thus, the aim of this study was to 
investigate the functional significance of miR-150-5p and miR-150-3p in naïve prostate cancer 
(PCa) and castration-resistant prostate cancer (CRPC). Ectopic expression assays showed that 
both strands of miRNAs significantly suppressed cancer cell migration and invasion. Our 
strategies of miRNA target searching demonstrated that SPOCK1 (SPARC/osteonectin, cwcv, 
and kazal like domains proteoglycan 1) was directly regulated by miR-150-5p and miR-150-3p. 
Knockdown of SPOCK1 by siRNA inhibited cancer cell aggressiveness. Moreover, 
overexpression of SPOCK1 was observed in naïve PCa and CRPC tissues. Taken together, dual 
strands of pre-miR-150 (miR-150-5p and miR-150-3p) acted as antitumor miRNAs in naïve PCa 
and CRPC cells. Expression of oncogenic SPOCK1 was involved in naïve PCa and CRPC 
pathogenesis. Novel approaches to analysis of antitumor miRNA-regulated RNA networks in 
cancer cells may provide new insights into the pathogenic mechanisms of naïve PCa and CRPC. 
 
  
  
INTRODUCTION 
Prostate cancer (PCa) is the most frequently diagnosed cancer among men in developed 
countries.(1) Although PCa is initially responsive to androgen-deprivation therapy (ADT), most 
patients experience disease relapse and develop castration-resistant prostate cancer (CRPC).(2) 
The survival rate of patients with CRPC is poor owing to the occurrence of metastasis,(3) and 
patients with metastatic CRPC cannot be effectively treated using recently developed molecular-
targeted therapies.(2, 3) Therefore, new treatment strategies are needed for these patients. The 
molecular mechanisms underlying the aggressiveness of CRPC cells and the acquisition of 
treatment resistance are still unclear. 
MicroRNAs (miRNAs) are noncoding RNAs that act as sequence-specific fine tuners for 
regulating the expression levels of proteins and RNAs.(4, 5) Notably, a single miRNA can 
regulate a large number of RNA transcripts in human cells.(6) Accordingly, dysregulation of 
miRNAs can disrupt the tightly regulated RNA networks in cancer cells, leading to cancer cell 
initiation, development, metastasis, and drug resistance.(7, 8) The discovery of miRNAs has 
complicated the analysis of intracellular RNA networks in cancer.  
We recently constructed an RNA-sequence based miRNA expression signature using 
autopsy specimens from patients with CRPC.(9) To elucidate the miRNA-mediated RNA 
networks in metastatic CRPC, we have sequentially identified antitumor miRNAs and 
oncogenic genes regulated by these miRNAs based on our miRNA expression signatures.(9, 10) 
Analysis of our miRNA signatures, including that in CRPC, has shown that both strands of pre-
miR-150, i.e., miR-150-5p (the guide strand) and miR-150-3p (the passenger strand), are 
significantly reduced in cancer tissues.(9)  
In miRNA biogenesis, pre-miRNA is cleaved by Dicer into the miRNA duplex, 
containing the guide and passenger strands. The mature guide strand miRNA is incorporated 
into the RNA-induced silencing complex (RISC) and represses mRNA translation or cleaves 
mRNA.(11) In contrast, the passenger strand of miRNA was previously thought to be degraded 
and to have no function.(12-14) However, our expression data have contradicted this established 
miRNA theory. We hypothesized that the passenger strand of miR-150-3p may have functions in 
naïve PCa and CRPC cells by targeting novel oncogenic genes. Accordingly, in this study, we 
aimed to investigate the functional significance of miR-150-5p and miR-150-3p in naïve PCa 
and CRPC cells and to identify oncogenic genes involved in the pathogenesis of the disease. 
 
 
MATERIALS AND METHODS 
Clinical prostate specimens  
Clinical prostate specimens were obtained from patients admitted to Teikyo University 
  
Chiba Medical Center from 2014 to 2015. All patients had elevated prostate-specific antigen 
(PSA) and had undergone transrectal biopsies for definitive cancer diagnoses. Particularly, in 
patients with CRPC, neuroendocrine differentiation was excluded. The patient backgrounds are 
summarized in Table 1. Samples were staged according to the UICC TNM classification.(15) 
All patients in this study provided written informed consent for tissue donation for research 
purposes. The protocol was approved by the Institutional Review Boards of Chiba University 
and Teikyo University.  
 
Tissue collection and cell culture 
Prostate tissues were immersed in RNAlater (Thermo Fisher Scientific, Waltham, MA, 
USA) and stored at 4°C until RNA extraction. Human prostate cancer cells (PC3 and PC3M 
cells) were obtained from the American Type Culture Collection (Manassas, VA, USA). 
 
Quantitative real-time reverse transcription polymerase chain reaction (RT-q-PCR) 
Stem-loop RT-PCR (TaqMan MicroRNA Assays; product ID: 000473 for miR-150-5p and 
002637 for miR-150-3p; Applied Biosystems, Foster City, CA, USA) was used to this assays. 
TaqMan probes and primers for SPOCK1 (product ID: Hs00270274_m1; Applied Biosystems) 
were assay-on-demand gene expression products. We used GUSB (product ID: 
Hs00939627_m1; Applied Biosystems), GAPDH (product ID: Hs02758991_g1; Applied 
Biosystems), and RNU48 (product ID: 001006; Applied Biosystems) as internal controls. 
 
Cell proliferation, migration, and invasion assays 
Cell proliferation, migration, and invasion assays were carried out as previously 
described.(9, 10) 
 
Argonaute 2(AGO2)-bound miRNA isolation by immunoprecipitation 
PC3 cells were transfected with 10 nM miRNA by reverse transfection and plated in 10-
cm plates at 1 × 105 cells/mL. After 48 h, immunoprecipitation was performed using a 
microRNA Isolation Kit, Human Ago2 (Wako, Osaka, Japan) according to the manufacturer’s 
protocol. Expression levels of miRNAs bound to Ago2 were measured by TaqMan RT-qPCR. 
miRNA expression data were normalized to the expression of miR-26a (product ID: 000404; 
Applied Biosystems), which was not affected by miR-150-5p and miR-150-3p.  
 
Western blot analysis 
Immunoblotting was conducted with diluted monoclonal anti-SPOCK1 antibodies (1:100 
dilution; sc-398782; Santa Cruz Biotechnology, Santa Cruz, CA, USA) and with diluted anti-
  
glyceraldehyde 3-phosphate dehydrogenase (GAPDH) antibodies (1:1000 dilution; ab8245; 
Abcam, Cambridge, UK) as a loading control. The procedures were performed as previously 
described.(16) 
 
Selection of putative target genes regulated by miR-150-5p and miR-150-3p in PCa cells 
To identify miR-150-5p and miR-150-3p target genes, we analyzed gene expression 
profile (Gene Expression Omnibus database; accession number: GSE29079). Gene expression 
data were obtained from miR-150-5p and miR-150-3p transfectant PC3 cells (A SurePrint G3 
Human 60K, Agilent Technologies, Santa Clara, CA, USA). We merged these datasets and 
selected putative miR-150-5p and miR-150-3p target genes using the TargetScan database 
(Release 7.1; http://www.targetscan.org/vert_71/). 
 
Plasmid construction and dual-luciferase assays 
The partial wide-type sequences of the 3’-untranslated region (UTR) of SPOCK1 or those 
with a deleted miR-150-5p or miR-150-3p target site were inserted in the psiCHECK-2 vector 
(C8021; Promega, Madison, WI, USA). Alternatively, we used sequences that were missing the 
miR-150-5p target site (position 182-188) or miR-150-3p target sites (position 1477-1483, 
position 1749–1756, or position 2593–2599). The procedure for dual-luciferase reporter assays 
was described previously.(17) 
 
Immunohistochemistry using tissue microarrays 
We used a tissue microarray of prostate cancer samples obtained from Provitro (Berlin, 
Germany; cat. no. 401-2209, Lot no. 146.1P), which contained a total of 71 prostate samples 
(PCa specimens: n = 58, prostatic intraepithelial neoplasia: n = 10, and normal prostate samples: 
n = 10). Detailed information on these samples is summarized in Table 2. The tissue microarray 
was immunostained following the manufacturer’s protocol, as described previously.(10, 18) 
 
Statistical analysis 
The relationships between 2 groups and expression values obtained by RT-PCR were 
analyzed using Mann-Whitney U-tests. The correlations between miR-150-5p and miR-150-3p 
expression were evaluated using Spearman’s rank test. The relationships among more than 3 
variables and numerical values were analyzed using Bonferroni-adjusted Mann-Whitney U-
tests. We used Expert StatView software (version 5.0 SAS Institute Inc., Cary, NC, USA) for 
these analyses. 
 
 
  
RESULTS 
The expression levels of miR-150-5p and miR-150-3p in naïve PCa and CRPC specimens 
and cell lines 
We evaluated the expression levels of miR-150-5p and miR-150-3p in PCa tissues (PCa: n 
= 17, CRPC: n = 5), normal tissues (non-PCa: n = 17), and PCa cell lines (PC3 and PC3M 
cells). The patients’ backgrounds are summarized in Table 1. The expression levels of miR-150-
5p and miR-150-3p were significantly lower in PCa and CRPC tissues than normal tissues (miR-
150-5p: P = 0.0266 and P = 0.018, respectively; miR-150-3p: P = 0.0025 and P = 0.0002, 
respectively; Figure 1A). There was a positive correlation between expression levels of miR-
150-5p and miR-150-3p (r = 0.854, P < 0.0001; Figure 1B). 
 
Effects of ectopic expression of miR-150-5p and miR-150-3p on cell proliferation, 
migration, and invasion assays in PCa cell lines 
To examine the functional roles of miR-150-5p and miR-150-3p, we performed gain-of-
function studies by using PC3 and PC3M cells transfected with mature miRNAs.  
XTT assays revealed that proliferation was significantly inhibited in PC3 and PC3M cells 
transfected with miR-150-5p and miR-150-3p in comparison with that of mock or miR-control-
transfected cells (P < 0.0001; Figure 1C). Wound-healing and Matrigel invasion assays 
demonstrated significant inhibition of cell migration and invasion in both miR-150-5p and miR-
150-3p transfectants (P < 0.0001; Figures 1D and 1E).  
 
Both miR-150-5p and miR-150-3p bound to Ago2 
We hypothesized that both miR-150-5p and miR-150-3p may be incorporated into and 
function as part of the RISC. To test this hypothesis, we performed immunoprecipitation with 
antibodies targeting Ago2, which plays a central role in the RISC. After transfection with miR-
150-5p or miR-150-3p, Ago2-bound miRNAs were isolated, and RT-qPCR was carried out to 
determine whether miR-150-5p and miR-150-3p bound to Ago2(Figure 2A).  
After transfection with miR-150-5p and immunoprecipitation by anti-Ago2 antibodies, 
miR-150-5p levels were significantly higher than those of mock- or miR control-transfected 
cells and those of miR-150-3p-transfected PC3 cells (P < 0.0001; Figure2B). Similarly, after 
transfection with miR-150-3p and immunoprecipitation by anti-Ago2 antibodies, miR-150-3p 
levels were significantly higher than those of mock- or miR control-transfected cells and those 
of miR-150-5p-transfected PC3 cells (P < 0.0001; Figure 2B).  
 
 
Screening of target genes regulated by miR-150-3p in PCa cells 
  
To obtain further insights into the molecular mechanisms regulated by antitumor miR-
150-3p in PCa cells, we screened these miRNA-regulated genes by using in silico and genome-
wide gene expression analyses. First, we undertook genome-wide gene expression analysis 
using PC3 cells.      
Analysis of the TargetScan database showed that 2,558 genes had putative target sites for 
miR-150-3p in their 3’-UTRs. Next, we screened 328 of these genes using genome-wide gene 
expression analysis. Finally, we found 14 genes that were upregulated (fold-change log2 > 0.5) 
in cancer tissues by GEO database analyses (GEO accession number: GSE29079). Our strategy 
for analysis is shown in Figure 3. Putative target genes of miR-150-3p are summarized in Table 
3. Among these candidate genes, SPOCK1 had a putative binding site for miR-150-5p according 
to the TargetScan database. Therefore, we focused on SPOCK1 as a candidate target gene of the 
dual strands of pre-miR-150 and performed further investigations of this target in PCa. 
 
Regulation of SPOCK1 expression by miR-150-5p and miR-150-3p in PCa cells 
Our studies revealed that SPOCK1 mRNA was significantly reduced in both miR-150-5p 
and miR-150-3p transfectants in comparison with those in mock or miR-control transfectants (P 
< 0.0001 and P < 0.0001; Figure 4A). Expression of SPOCK1 protein was also repressed in 
these miRNAs transfectants (Figure 4B).  
Target prediction databases indicated that miR-150-5p had one putative target site in the 
3'-UTR of SPOCK1 (Figure 4C). Likewise, miR-150-3p had three putative target sites (Figure 
2C). To determine whether SPOCK1 mRNA contained functional target sites, we performed a 
dual luciferase reporter assay. 
The TargetScan database identified one putative target sites in the 3’-UTR of SPOCK1 for 
miR-150-5p (position 182-188) and three target sites of SPOCK1 for miR-150-3p (positions 
1477-1483, 1749-1756, and 2593-2599). We used vectors encoding a partial wild-type sequence 
of the 3’-UTR of SPOCK1 mRNA, including the predicted miR-150-5p and miR-150-3p target 
site, or a vector lacking the miR-150-5p and miR-150-3p target sites. We found that the 
luminescence intensity was significantly reduced by co-transfection with miR-150-5p or miR-
150-3p and the vector carrying the wild-type 3’-UTR of SPOCK1 (P < 0.05; Figure 4D). 
 
Effects of silencing SPOCK1 on cell proliferation, migration, and invasion in PCa cells 
We evaluated the knockdown efficiency of si-SPOCK1 transfection in PC3 cells. Our 
present data showed that si-SPOCK1 transfection effectively downregulated SPOCK1 
expression in PC3 and PC3M cells (Figures 5A and 5B).  
Functional assays demonstrated that cell proliferation, migration, and invasion were 
inhibited in si-SPOCK1 transfectants compared with those in mock- or miR control-transfected 
  
cells (P < 0.0001, Figures 5C–5E). 
 
Analysis of SPOCK1 expression in naïve PCa and CRPC clinical specimens by 
immunohistochemistry 
Next, we examined the expression levels of SPOCK1 in naïve PCa specimens by 
immunohistochemical staining. SPOCK1 was strongly expressed in several cancer tissues, 
while low expression was observed in normal tissues (Figure. 6A). Moreover, the expression 
score for SPOCK1 protein was significantly higher in PCa tissues than in normal tissues (P < 
0.001, Figure 6B). The patients’ backgrounds and clinicopathological characteristics are 
summarized in Table 2.  
To analyze SPOCK1 protein expression, immunohistochemistry was performed with 
CRPC specimens. Immunohistochemical staining demonstrated high expression of SPOCK1 in 
CRPC tissues. SPOCK1 was strongly expressed in the cytoplasm of the PCa cells almost in the 
same area where PSA expressed (Figure 6C). 
 
 
DISCUSSION 
Androgen-dependent PCa initially responds to ADT, which can result in disease control. 
However, most PCa cells eventually acquire ADT-resistance mechanisms. Moreover, there are 
no curative treatments for patients with metastatic CRPC.(19) One of the main challenges in 
treating CRPC is controlling aggressive, lethal metastatic PCa cells. We believe identification of 
the genes and pathways responsible for metastasis may lead to the development of new 
therapeutic strategies. Accordingly, we have focused on identifying antitumor miRNAs and 
oncogenic RNA networks mediated by these miRNAs in naïve PCa and CRPC cells.(9, 20, 21) 
For example, antitumor miR-223 inhibits cancer cell migration and invasion by targeting ITGA3 
and ITGB1.(18) Antitumor miR-218 suppresses migration and invasion by regulating 
LASP1.(22) Moreover, antitumor miRNAs (miR-26a/b, miR-29a/b/c, and miR-218) function 
cooperatively to suppress metastasis-promoting LOXL.(23)  
In this study, we demonstrated that the dual strands of pre-miR-150, i.e., miR-150-5p and 
miR-150-3p, acted as antitumor miRNAs in naïve PCa and CRPC cells. According to the 
miRNA database (miRBase: http://www.mirbase.org/), miR-150-5p is a guide strand of pre-miR-
150, and miR-150-3p is the corresponding passenger strand. Previous studies have shown that 
miR-150-5p (the guide strand) is frequently downregulated in cancer tissues and functions as an 
antitumor miRNA in several types of cancer.(24-26) In this study, we focused on miR-150-3p 
(the passenger strand) and investigated the antitumor roles of this miRNA in naïve PCa and 
CRPC cells because no prior studies had evaluated the functions of miR-150-3p in cancer cells. 
  
Passenger strands of miRNA are thought to be degraded and are not expected to be 
incorporated into the RISC.(4) However, our data showed that the passenger strand of miR-150 
was incorporated into the RISC in PCa cells, and this is the first report of the antitumor function 
of miR-150-3p in cancer cells. Our recent studies demonstrated that miR-145-3p (the passenger 
strand of pre-miR-145) acted as an antitumor miRNA targeting oncogenic UHRF1 and MTDH 
in bladder and lung cancer, respectively.(16, 27) Similarly, we confirmed the antitumor function 
of miR-139-3p (a passenger strand of pre-miR-139) in bladder cancer.(17) These findings 
suggested that the passenger strands of miRNAs may have some biological functions in human 
cells, similar to the guide strands of miRNAs. The involvement of passenger strand miRNAs in 
the regulation of cellular processes is a novel concept in RNA research. 
One of the main challenges in miRNA studies is to seek out miRNA targeting genes and 
RNA networks mediated by these miRNAs in cancer cells. We revealed that SPOCK1 was a 
direct target of miR-150-3p in PCa cells. Moreover, we demonstrated the overexpression of 
SPOCK1 in naïve PCa and CRPC clinical specimens. SPOCK1/testican-1 belongs to the Ca2+-
binding proteoglycan family, which includes SPARC, testican-2, and testican-3.(28) 
Overexpression of SPOCK1 was observed in several cancers and has been shown to play pivotal 
roles in cancer cell progression, metastasis, and drug resistance.(29-31) SPOCK1 is upregulated 
in lung cancer and is associated with metastasis and survival.(32) Interestingly, ectopic 
expression of SPOCK1 induces the epithelial–mesenchymal transition (EMT) in lung cancer 
cells.(33) Another study demonstrated that SPOCK1 induces MET-dependent EMT signaling in 
lapatinib-resistant gastric cancer.(34) Several reports have indicated that tyrosine kinase 
receptor inhibitors (TKIs) can frequently cause the acquisition of TKI resistance in cells and that 
the EMT is deeply involved in these events.(35, 36) These findings suggest that SPOCK1 
mediates the EMT signaling to regulate cancer cell aggressiveness and drug resistance. 
Most patients with PCa exhibit ADT failure and progress to CRPC with metastasis. 
Moreover, no curative treatments are available for advanced CRPC with metastasis.(37) In 
CRPC cells, the EMT is associated with metastatic processes and is involved in drug 
resistance.(38) Interestingly, androgens and androgen receptor-mediated signaling enhance the 
EMT and cancer cell aggressiveness.(39) Transforming growth factor  (TGF ) is a pivotal 
player that induces the EMT in cancer cells.(40) Increased expression of TGF  and EMT-
related proteins has been observed in CRPC bone metastasis.(41) Interestingly, expression of 
SPOCK1 is elevated by TGF  treatment in lung cancer cells, suggesting that SPOCK1 mediates 
downstream TGF signaling.(33) We suggest that SPOCK1 expression may be related to 
induction of TGF  signaling and epigenetic regulation of miR-150-5p and miR-150-3p in naïve 
PCa and CRPC cells. A recent study showed that overexpression of SPOCK1 in RWPE-1 cells 
(non-neoplastic adult human prostatic epithelial cells) promotes cell viability and cell migration 
  
and invasion abilities.(42) These findings were supported by our present data. Thus, the 
expression of SPOCK1 may be involved in the pathogenesis of naïve PCa and CRPC, and 
SPOCK1-mediated signaling may be a promising therapeutic target in this disease.  
In summary, the dual strands of pre-miR-150, i.e., miR-150-5p and miR-150-3p, were 
significantly reduced in naïve PCa and CRPC tissues and acted as antitumor mRNAs. The 
passenger strand of miR-150-3p was found to have a specific function in cancer cells. SPOCK1 
was directly regulated by dual strands of miR-150-5p and miR-150-3p in PCa cells. 
Overexpression of SPOCK1 was confirmed in naïve PCa and CRPC tissues and acted as an 
oncogene in this disease. Elucidation of miR-150/SPOCK1-mediated molecular networks may 
lead to a better understanding of the pathogenesis of naïve PCa and CRPC and facilitate the 
development of new treatment strategies. 
 
 
CONFLICT OF INTEREST 
The authors declare that they have no conflicts of interest. 
 
 
ACKNOWLEDGEMENTS 
The present study was supported by KAKENHI(C) grant 15K10801, (C) 15K20071, (C) 
16K20125, and (B) 25293333. 
 
 
  
  
References 
 
1. Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017. CA: a cancer journal for 
clinicians;67(1):7-30,2017. 
2. Sridhar SS, Freedland SJ, Gleave ME, Higano C, Mulders P, Parker C, et al. Castration-resistant 
prostate cancer: from new pathophysiology to new treatment. European urology;65(2):289-
299,2014. 
3. Sturge J, Caley MP, Waxman J. Bone metastasis in prostate cancer: emerging therapeutic 
strategies. Nature reviews Clinical oncology;8(6):357-368,2011. 
4. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell;116(2):281-
297,2004. 
5. Carthew RW, Sontheimer EJ. Origins and Mechanisms of miRNAs and siRNAs. 
Cell;136(4):642-655,2009. 
6. Zhang Y, Wang Z, Gemeinhart RA. Progress in microRNA delivery. J Control 
Release;172(3):962-974,2013. 
7. Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell;136(2):215-233,2009. 
8. Nelson KM, Weiss GJ. MicroRNAs and cancer: past, present, and potential future. Molecular 
cancer therapeutics;7(12):3655-3660,2008. 
9. Goto Y, Kojima S, Nishikawa R, Kurozumi A, Kato M, Enokida H, et al. MicroRNA expression 
signature of castration-resistant prostate cancer: the microRNA-221/222 cluster functions as a 
tumour suppressor and disease progression marker. Br J Cancer;113(7):1055-1065,2015. 
10. Okato A, Goto Y, Kurozumi A, Kato M, Kojima S, Matsushita R, et al. Direct regulation of 
LAMP1 by tumor-suppressive microRNA-320a in prostate cancer. Int J Oncol;49(1):111-
122,2016. 
11. Gregory RI, Chendrimada TP, Cooch N, Shiekhattar R. Human RISC couples microRNA 
biogenesis and posttranscriptional gene silencing. Cell;123(4):631-640,2005. 
12. Chendrimada TP, Gregory RI, Kumaraswamy E, Norman J, Cooch N, Nishikura K, et al. TRBP 
recruits the Dicer complex to Ago2 for microRNA processing and gene silencing. 
Nature;436(7051):740-744,2005. 
13. Hutvagner G, Zamore PD. A microRNA in a multiple-turnover RNAi enzyme complex. 
Science;297(5589):2056-2060,2002. 
14. Matranga C, Tomari Y, Shin C, Bartel DP, Zamore PD. Passenger-strand cleavage facilitates 
assembly of siRNA into Ago2-containing RNAi enzyme complexes. Cell;123(4):607-620,2005. 
15. L.H. Sobin MKG, Ch. Wittekind. TNM Classification of Malignant Tumours seventh edition. 
Wiley-Blackwell : Chichester UK 2009. 
16. Mataki H, Seki N, Mizuno K, Nohata N, Kamikawaji K, Kumamoto T, et al. Dual-strand tumor-
  
suppressor microRNA-145 (miR-145-5p and miR-145-3p) coordinately targeted MTDH in lung 
squamous cell carcinoma. Oncotarget;7(44):72084-72098,2016. 
17. Yonemori M, Seki N, Yoshino H, Matsushita R, Miyamoto K, Nakagawa M, et al. Dual tumor-
suppressors miR-139-5p and miR-139-3p targeting matrix metalloprotease 11 in bladder cancer. 
Cancer Sci;107(9):1233-1242,2016. 
18. Kurozumi A, Goto Y, Matsushita R, Fukumoto I, Kato M, Nishikawa R, et al. Tumor-suppressive 
microRNA-223 inhibits cancer cell migration and invasion by targeting ITGA3/ITGB1 signaling 
in prostate cancer. Cancer Sci;107(1):84-94,2016. 
19. Semenas J, Allegrucci C, Boorjian SA, Mongan NP, Persson JL. Overcoming drug resistance and 
treating advanced prostate cancer. Current drug targets;13(10):1308-1323,2012. 
20. Fuse M, Kojima S, Enokida H, Chiyomaru T, Yoshino H, Nohata N, et al. Tumor suppressive 
microRNAs (miR-222 and miR-31) regulate molecular pathways based on microRNA 
expression signature in prostate cancer. J Hum Genet;57(11):691-699,2012. 
21. Goto Y, Kurozumi A, Enokida H, Ichikawa T, Seki N. Functional significance of aberrantly 
expressed microRNAs in prostate cancer. Int J Urol;22(3):242-252,2015. 
22. Nishikawa R, Goto Y, Sakamoto S, Chiyomaru T, Enokida H, Kojima S, et al. Tumor-
suppressive microRNA-218 inhibits cancer cell migration and invasion via targeting of LASP1 
in prostate cancer. Cancer Sci;105(7):802-811,2014. 
23. Kato M, Kurozumi A, Goto Y, Matsushita R, Okato A, Nishikawa R, et al. Regulation of 
metastasis-promoting LOXL2 gene expression by antitumor microRNAs in prostate cancer. J 
Hum Genet;62(1):123-132,2017. 
24. Abe F, Kitadate A, Ikeda S, Yamashita J, Nakanishi H, Takahashi N, et al. Histone deacetylase 
inhibitors inhibit metastasis by restoring a tumor suppressive microRNA-150 in advanced 
cutaneous T-cell lymphoma. Oncotarget,2016. 
25. Srivastava SK, Bhardwaj A, Singh S, Arora S, Wang B, Grizzle WE, et al. MicroRNA-150 
directly targets MUC4 and suppresses growth and malignant behavior of pancreatic cancer cells. 
Carcinogenesis;32(12):1832-1839,2011. 
26. Qu Y, Pan S, Kang M, Dong R, Zhao J. MicroRNA-150 functions as a tumor suppressor in 
osteosarcoma by targeting IGF2BP1. Tumour Biol,2015. 
27. Matsushita R, Yoshino H, Enokida H, Goto Y, Miyamoto K, Yonemori M, et al. Regulation of 
UHRF1 by dual-strand tumor-suppressor microRNA-145 (miR-145-5p and miR-145-3p): 
Inhibition of bladder cancer cell aggressiveness. Oncotarget,2016. 
28. Bradshaw AD. Diverse biological functions of the SPARC family of proteins. The international 
journal of biochemistry & cell biology;44(3):480-488,2012. 
29. Li Y, Chen L, Chan TH, Liu M, Kong KL, Qiu JL, et al. SPOCK1 is regulated by CHD1L and 
blocks apoptosis and promotes HCC cell invasiveness and metastasis in mice. 
  
Gastroenterology;144(1):179-191.e174,2013. 
30. Ma LJ, Wu WJ, Wang YH, Wu TF, Liang PI, Chang IW, et al. SPOCK1 Overexpression Confers 
a Poor Prognosis in Urothelial Carcinoma. Journal of Cancer;7(4):467-476,2016. 
31. Shu YJ, Weng H, Ye YY, Hu YP, Bao RF, Cao Y, et al. SPOCK1 as a potential cancer prognostic 
marker promotes the proliferation and metastasis of gallbladder cancer cells by activating the 
PI3K/AKT pathway. Mol Cancer;14:12,2015. 
32. Kusakabe M, Kutomi T, Watanabe K, Emoto N, Aki N, Kage H, et al. Identification of G0S2 as a 
gene frequently methylated in squamous lung cancer by combination of in silico and 
experimental approaches. Int J Cancer;126(8):1895-1902,2010. 
33. Miao L, Wang Y, Xia H, Yao C, Cai H, Song Y. SPOCK1 is a novel transforming growth factor-
beta target gene that regulates lung cancer cell epithelial-mesenchymal transition. Biochem 
Biophys Res Commun;440(4):792-797,2013. 
34. Kim HP, Han SW, Song SH, Jeong EG, Lee MY, Hwang D, et al. Testican-1-mediated epithelial-
mesenchymal transition signaling confers acquired resistance to lapatinib in HER2-positive 
gastric cancer. Oncogene;33(25):3334-3341,2014. 
35. Uramoto H, Iwata T, Onitsuka T, Shimokawa H, Hanagiri T, Oyama T. Epithelial-mesenchymal 
transition in EGFR-TKI acquired resistant lung adenocarcinoma. Anticancer 
research;30(7):2513-2517,2010. 
36. Choe C, Shin YS, Kim C, Choi SJ, Lee J, Kim SY, et al. Crosstalk with cancer-associated 
fibroblasts induces resistance of non-small cell lung cancer cells to epidermal growth factor 
receptor tyrosine kinase inhibition. OncoTargets and therapy;8:3665-3678,2015. 
37. Crawford ED, Higano CS, Shore ND, Hussain M, Petrylak DP. Treating Patients with Metastatic 
Castration Resistant Prostate Cancer: A Comprehensive Review of Available Therapies. J 
Urol;194(6):1537-1547,2015. 
38. Martin SK, Pu H, Penticuff JC, Cao Z, Horbinski C, Kyprianou N. Multinucleation and 
Mesenchymal-to-Epithelial Transition Alleviate Resistance to Combined Cabazitaxel and 
Antiandrogen Therapy in Advanced Prostate Cancer. Cancer research;76(4):912-926,2016. 
39. Nakazawa M, Kyprianou N. Epithelial-mesenchymal-transition regulators in prostate cancer: 
Androgens and beyond. The Journal of steroid biochemistry and molecular biology;166:84-
90,2017. 
40. Xu J, Lamouille S, Derynck R. TGF-beta-induced epithelial to mesenchymal transition. Cell 
research;19(2):156-172,2009. 
41. Haider M, Zhang X, Coleman I, Ericson N, True LD, Lam HM, et al. Epithelial mesenchymal-
like transition occurs in a subset of cells in castration resistant prostate cancer bone metastases. 
Clinical & experimental metastasis;33(3):239-248,2016. 
42. Chen Q, Yao YT, Xu H, Chen YB, Gu M, Cai ZK, et al. SPOCK1 promotes tumor growth and 
  
metastasis in human prostate cancer. Drug design, development and therapy;10:2311-2321,2016. 
 
  
  
Figure Legends 
Figure 1. Expression levels of miR-150-5p and miR-150-3p and functional assays in PCa cell 
lines (PC3 and PC3M cells) following miR-150-5p and miR-150-3p transfection. 
(A) Expression levels of miR-150-5p and miR-150-3p in naïve PCa and CRPC clinical 
specimens and cell lines were determined by qRT-PCR. Data were normalized to RNU48 
expression. (B) Cell proliferation was determined by XTT assays 72 h after transfection with 10 
nM miR-150-5p and miR-150-3p. *, P < 0.0001. (C) Cell migration activity was determined by 
migration assays. *, P < 0.0001. (D) Cell invasion activity was determined using Matrigel 
invasion assays. *, P < 0.0001. 
 
Figure 2. Both miR-150-5p and miR-150-3p bound to Ago2. 
(A) Schematic illustration of miRNA detection method. Isolation of RISC incorporated 
miRNAs by Ago-2 immunoprecipitation. (B) Expression levels of miR-150-5p and miR-150-3p 
after transfection with miR-150-3p following immunoprecipitation by Ago2 (P < 0.0001). 
 
Figure 3. The strategy for analysis of miR-150-3p target genes in PCa cells. 
A total of 2,558 genes were annotated as miR-150-3p putative target genes in the TargetScan 
database (release 7.1). Next, we merged the data for gene expression analysis data in miR-150-
3p transfectants, and we analyzed gene expression with the available GEO data set (GSE29079). 
The analyses showed that 14 genes were putative targets of miR-150-3p regulation in PCa cells. 
 
Figure 4. Direct regulation of SPOCK1 by miR-150-5p and miR-150-3p in PCa cell lines. 
(A) SPOCK1 mRNA expression in PCa cell lines was evaluated by qRT-PCR 72 h after 
transfection with 10 nM miR-150-5p and miR-150-3p. GUSB was used as an internal control. *, 
P < 0.0001. (B) SPOCK1 protein expression in PCa cell lines was evaluated by western blot 
analyses 72 h after transfection with miR-150-5p and miR-150-3p. GAPDH was used as a 
loading control. (C) miR-150-5p or miR-150-3p binding sites in the 3′-UTR of SPOCK1 mRNA. 
(D) Dual Luciferase reporter assays using vectors encoding putative miR-150-5p and miR-150-
3p target sites of the SPOCK1 3′ UTR (positions 182-188, 1477–1483, 1749-1756, and 2593-
2599) for both wild-type and deleted regions. Normalized data were calculated as ratios of 
Renilla/firefly luciferase activities. *P < 0.05. 
 
Figure 5. SPOCK1 mRNA and SPOCK1 protein expression after si-SPCOK1 transfection and 
the effects of SPOCK1 silencing in PCa cell lines. 
(A) SPOCK1 mRNA expression in PCa cell lines was evaluated by qRT-PCR 72 h after 
transfection with 10 nM si-SPOCK1_1 or si-SPOCK1_2. GAPDH was used as an internal 
  
control. (B) SPOCK1 protein expression in PCa cell lines was evaluated by western blot 
analysis 72 h after transfection with siRNAs. GAPDH was used as a loading control. (C) Cell 
proliferation was determined using XTT assays 72 h after transfection with si-SPOCK1_1 or si-
SPOCK1_2. *, P < 0.0001. (D) Cell migration activity was determined by migration assays. *, P 
< 0.0001. (E) Cell invasion activity was determined using Matrigel invasion assays. *, P < 
0.0001. 
 
Figure 6. Immunohistochemical staining of SPOCK1 protein in naïve PCa and CRPC 
specimens. 
(A) Immunohistochemical staining of SPOCK1 in naïve PCa using a tissue microarray. 
SPOCK1 was strongly expressed in several cancer tissues, while low expression was observed 
in normal tissues. (B) Quantification of SPOCK1 expression in PCa (n = 58), PIN (n = 10), and 
normal prostatic tissue (n = 10) by tissue microarray. (C) Expression of SPOCK1 in CRPC 
specimens. SPOCK1 was strongly expressed in cancer lesions, similar to PSA.  
 
Table 1. Characteristics of patients with non-PCa and naïve PCa and CRPC. 
 
Table 2. Characteristics of patients, as evaluated using immunohistochemistry. 
 
Table 3. Putative target genes regulated by miR-150-3p in PCa cells. 
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